The US FDA has recently proposed a new draft framework that enables pharma manufacturers to add software to a drug label if they can demonstrate that the software adds clinical benefit to t
Treatments emerging from the digital therapeutics space were once greeted with optimism, due to the potential to aid patients’ health through technology, rather than pharmaceuticals.
Clinical trials historically struggled with several key inefficiencies, many of which became painfully apparent during the COVID-19 pandemic, such as the traditional paper-based, manual rev
Security and privacy within biotech are critical points of consideration and discussion as the industry continues to innovate at speed, and it is such aspects that are central to today’s po
